M Elizabeth H Hammond1, Monica P Revelo2, Dylan V Miller3, Gregory L Snow4, Deborah Budge5, Josef Stehlik6, Kimberly M Molina7, Craig H Selzman8, Stavros G Drakos9, Alharethi Rami A5, Jose N Nativi-Nicolau9, Bruce B Reid5, Abdallah G Kfoury5. 1. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program, Salt Lake City, Utah; Department of Pathology, Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, Utah; Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah. Electronic address: liz.hammond@hotmail.com. 2. Department of Pathology, Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, Utah; Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah. 3. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program, Salt Lake City, Utah; Department of Pathology, Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, Utah; Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah. 4. Statistical Data Center, Intermountain Healthcare, Salt Lake City, Utah. 5. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program, Salt Lake City, Utah; Cardiovascular Clinical Program, Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, Utah. 6. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program, Salt Lake City, Utah; Department of Cardiology, University of Utah School of Medicine, Salt Lake City, Utah; Department of Cardiology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, Utah. 7. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program, Salt Lake City, Utah; Department of Cardiology, Primary Childrens Hospital, Salt Lake City, Utah. 8. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program, Salt Lake City, Utah; Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah. 9. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program, Salt Lake City, Utah; Department of Cardiology, University of Utah School of Medicine, Salt Lake City, Utah.
Abstract
BACKGROUND: Antibody-mediated rejection (AMR) in cardiac transplant recipients is a serious form of rejection with adverse patient outcomes. The International Society of Heart and Lung Transplantation (ISHLT) has published a consensus schema for the pathologic diagnosis of various grades of antibody-mediated rejection (pathology antibody-mediated rejection [pAMR]). We sought to determine whether the ISHLT pAMR grading schema correlates with patient outcomes. METHODS: Using our database, which contains a semi-quantitative scoring of all pathologic descriptors of pAMR, we retrospectively used these descriptors to convert the previous AMR categories to the current ISHLT pAMR categories. Cox proportional hazard models were fit with cardiovascular (CV) death or retransplant as the outcome. The pAMR value was included as a categorical variable, and cellular rejection (CR) values were included in a separate model. RESULTS: There were 13,812 biopsies from 1,014 patients analyzed. The pAMR grades of pAMR1h, pAMR1i, and pAMR2 conferred comparable increased risk for CV mortality. Significantly increased risk of CV mortality was conferred by biopsies graded as severe AMR (pAMR3). CONCLUSIONS: The new ISHLT pAMR grading schema identifies patients at increased risk of CV mortality, consistent with risks published from several programs before 2011. The current schema is validated by this analysis in a large biopsy database. Because pAMR1h, pAMR1i, and pAMR2 have similar CV risks associated with them, the threshold for a positive diagnosis of pAMR should be re-evaluated in future iterations of the ISHLT schema.
BACKGROUND: Antibody-mediated rejection (AMR) in cardiac transplant recipients is a serious form of rejection with adverse patient outcomes. The International Society of Heart and Lung Transplantation (ISHLT) has published a consensus schema for the pathologic diagnosis of various grades of antibody-mediated rejection (pathology antibody-mediated rejection [pAMR]). We sought to determine whether the ISHLT pAMR grading schema correlates with patient outcomes. METHODS: Using our database, which contains a semi-quantitative scoring of all pathologic descriptors of pAMR, we retrospectively used these descriptors to convert the previous AMR categories to the current ISHLT pAMR categories. Cox proportional hazard models were fit with cardiovascular (CV) death or retransplant as the outcome. The pAMR value was included as a categorical variable, and cellular rejection (CR) values were included in a separate model. RESULTS: There were 13,812 biopsies from 1,014 patients analyzed. The pAMR grades of pAMR1h, pAMR1i, and pAMR2 conferred comparable increased risk for CV mortality. Significantly increased risk of CV mortality was conferred by biopsies graded as severe AMR (pAMR3). CONCLUSIONS: The new ISHLT pAMR grading schema identifies patients at increased risk of CV mortality, consistent with risks published from several programs before 2011. The current schema is validated by this analysis in a large biopsy database. Because pAMR1h, pAMR1i, and pAMR2 have similar CV risks associated with them, the threshold for a positive diagnosis of pAMR should be re-evaluated in future iterations of the ISHLT schema.
Authors: Benjamin S Mantell; Hector Cordero; Sarah B See; Kevin J Clerkin; Rodica Vasilescu; Charles C Marboe; Yoshifumi Naka; Susan Restaino; Paolo C Colombo; Linda J Addonizio; Maryjane A Farr; Emmanuel Zorn Journal: J Heart Lung Transplant Date: 2021-07-08 Impact factor: 10.247
Authors: P Bruneval; A Angelini; D Miller; L Potena; A Loupy; A Zeevi; E F Reed; D Dragun; N Reinsmoen; R N Smith; L West; S Tebutt; T Thum; M Haas; M Mengel; P Revelo; M Fedrigo; J P Duong Van Huyen; G J Berry Journal: Am J Transplant Date: 2016-12-12 Impact factor: 8.086
Authors: Tereza Nováková; Táňa Macháčková; Jan Novák; Petr Hude; Július Godava; Víta Žampachová; Jan Oppelt; Filip Zlámal; Petr Němec; Helena Bedáňová; Ondřej Slabý; Julie Bienertová-Vašků; Lenka Špinarová; Jan Krejčí Journal: Cells Date: 2019-11-06 Impact factor: 6.600
Authors: Giuseppe Milone; Claudia Bellofiore; Salvatore Leotta; Giulio Antonio Milone; Alessandra Cupri; Andrea Duminuco; Bruno Garibaldi; Giuseppe Palumbo Journal: J Clin Med Date: 2022-01-26 Impact factor: 4.241
Authors: Patrick Yerly; Samuel Rotman; Julien Regamey; Vincent Aubert; Stefania Aur; Matthias Kirsch; Roger Hullin; Manuel Pascual Journal: Xenotransplantation Date: 2022-01-10 Impact factor: 3.788